Natera Inc

Explore how Natera’s 2025‑26 strategy, analyst upgrades, and upcoming JPMHC reveal growth potential in prenatal genetics, boosting investor confidence.

Natera Inc. is set to present 14 studies at the European Society for Medical Oncology Congress, highlighting the clinical utility of its Signatera molecular residual disease platform, with analysts maintaining a positive outlook and price target of …

Natera Inc.’s stock price has dropped to 138.9 USD, raising concerns it may be oversold, amidst significant volatility in the biotechnology company’s stock over the past year.

Natera Inc., a biotechnology company, has showcased its genetic testing services, including Signatera, and experienced moderate stock price volatility over the past year.

Natera Inc. has made significant strides in biotechnology with groundbreaking data from its MRD assay, demonstrating exceptional performance in detecting minimal residual disease in colorectal cancer patients.

Natera Inc. is gearing up for its Q1 2025 earnings release, with analysts and investors eagerly awaiting insights into the company’s financial performance and its advancements in precision medicine and diagnostic solutions.